Aladdin Healthcare Technologies SE

  • WKN: A12ULL
  • ISIN: DE000A12ULL2
  • Land: Deutschland

Nachricht vom 30.07.2020 | 09:31

Aladdin Healthcare Technologies validates its proprietary Deep Learning Algorithms that significantly improve Drug Discovery Performance

DGAP-News: Aladdin Healthcare Technologies SE / Key word(s): Miscellaneous
30.07.2020 / 09:31
The issuer is solely responsible for the content of this announcement.

Aladdin Healthcare Technologies validates its proprietary Deep Learning Algorithms that significantly improve Drug Discovery Performance

- Aladdin develops a new deep learning method for drug discovery with superior performance validated on six chemical property and toxicity datasets

- Average prediction performance improved by 5-10% compared to other deep learning methods and by 20% compared to traditional computational methods

- 1.7 times more accurate than current state of the art methods

BERLIN/LONDON, July 30, 2020 - Aladdin Healthcare Technologies SE ("Aladdin", ISIN: DE000A12ULL2), a leading developer of Artificial Intelligence (AI) based healthcare diagnostics and drug discovery applications, had successfully validated its deep learning algorithms (Message Passing Neural Network) for drug discovery. Aladdin's technology has been validated last week by the 'International Joint Conferences on Artificial Intelligence (IJCAI)', a world leading organization for scientific purpose that spreads information on Artificial Intelligence (AI) by means of conferences at which educational materials like books and proceedings are presented.

Aladdin's team of experts developed a new deep learning-based graph model for molecular representation. A good drug candidate should not only be efficient but also have appropriate ADMET properties at a therapeutic dose. ADMET stands for absorption, distribution, metabolism, excretion, and toxicity of the drug candidate. Extensive experiments demonstrated that Aladdin's technology has achieved superior prediction performances (ADMET properties prediction) on six chemical property and toxicity datasets, improving other deep learning methods by 5-10% and traditional computational methods by over 20%. Furthermore, Aladdin's method is 1.7 times more accurate than other state-of-the-art methods when the training data set has no similar scaffold to the test set.

The successful results of Aladdin's deep learning algorithms have been accepted by the 29. International Joint Conference on AI among 4,717 valid submissions. The overall acceptance rate was only 12.6%.

Constructing proper representations of molecules lies at the core of numerous tasks such as molecular property prediction, virtual screening and drug design. Deep learning methods by using Graph neural networks, especially Message Passing Neural Networks (MPNN) and its variants, have recently made remarkable achievements in drug molecular modeling. Albeit powerful, the one-sided focus on atom (node) or bond (edge) information of existing MPNN methods leads to insufficient representations of the attributed molecular graphs. Aladdin has now developed a Communicative Message Passing Neural Network (CMPNN) to improve the molecular embedding by strengthening the message interactions between nodes and edges through a communicative kernel.

Wade Menpes-Smith, CEO of Aladdin Healthcare Technologies SE, comments: "This is a further validation of our world-class AI technology capability and another key milestone that is a catalyst for further breakthroughs in AI drug discovery."

Further information about Aladdin's method and results can be found on

About Aladdin Healthcare Technologies SE
Aladdin Healthcare Technologies SE (and its wholly owned subsidiary Aladdin Healthcare Technologies Ltd.) is a leading developer of AI healthcare diagnostics and drug discovery applications that can accelerate both early stage disease diagnosis and the end-to-end drug discovery process. Aladdin targets age-related diseases including a significant focus on Alzheimer's disease. Aladdin accomplishes this by collaborating with numerous partners within the global healthcare ecosystem to confidentially and securely gather targeted data including, genome, tabular, MRI, PET, cognition and other lifestyle data. These datasets are then analysed by our award-winning AI team and used to develop proprietary AI tools that can assist healthcare professionals to more accurately and efficiently diagnose age-related diseases. This new diagnostic process will save significant time and costs for healthcare professionals. Additionally, our AI drug discovery platform will be used by pharmaceutical Companies to speed up drug development, clinical trials and predict outcomes more accurately.

Website Link:

For further information:

Aladdin Healthcare Technologies Ltd.

24-26 Baltic Street West
London EC1Y 0UR
Phone +44 7714 719696

Contact Press
CROSS ALLIANCE communication GmbH
Sara Pinto
Phone +49 89 1250 90330



30.07.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

show this

Event im Fokus

14.-15.10.2020 Fachkonferenzen Finanzdienstleistungen und Technologie

11.-12.11.2020 Fachkonferenzen Software/IT und Branchenmix

Je nach aktueller Covid-19 Situation und den bestehenden Vorschriften für Versammlungen könnten die Fachkonferenzen im Herbst/Winter ggf. auch virtuell stattfinden.


Solutiance: Hohe Wachstumsdynamik durch den Ausbau des Plattformgeschäfts erwartet

Im ersten Halbjahr 2020 konnte Solutiance den eingeschlagenen Wachstumskurs fortsetzen und im Rahmen dessen die Gesamtleistung (Umsatz zzgl. Bestandsveränderungen) um rund 75 % auf 0,66 Mio. € (1. HJ 2019: 0,38 Mio. €) erhöhen. Das Unternehmen erwartet für das Gesamtjahr durch den weiteren Ausbau der softwarebasierten Dienstleistungen einen Umsatzsprung im Vergleich zum Vorjahr auf rund 3 Mio. €. Bei einem von uns ermittelten Kursziel von 4,85 € vergeben wir das Rating KAUFEN.

News im Fokus

Munich Re erzielt Quartalsergebnis von ca. 200 Mio. €

20. Oktober 2020, 15:37

Aktuelle Research-Studie

CytoTools AG

Original-Research: CytoTools AG (von BankM AG): Kaufen

19. Oktober 2020